Sarepta Therapeutics (SRPT) stock is reacting to first quarter earnings, where revenue of US$730.8 million compared with US$744.86 million a year earlier, while net income reached US$330.96 million after a prior net loss.

The latest earnings reversal has arrived after a volatile stretch, with a 90 day share price return of 35.23% and a 1 year total shareholder return decline of 37.28%, suggesting that recent momentum contrasts with longer term weakness.

If this kind of sharp move after results has your attention, it could be a good time to broaden your watchlist and check out 32 healthcare AI stocks

With Sarepta now profitable in the latest quarter, yet the stock still showing a 1 year total shareholder return decline and trading at a large modeled intrinsic discount, you have to ask: is this a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 6% Overvalued

The most followed narrative puts Sarepta’s fair value at $21.65, slightly below the last close of $23.03. This frames the recent earnings swing in a tighter valuation range.

The analysts have a consensus price target of $21.65 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $38.0, and the most bearish reporting a price target of just $5.0.

The fair value hinges on a company that is still expected to grow earnings rapidly while revenue trends move the other way. Margin rebuild, share count changes and a higher future earnings multiple all need to line up for this story to work.

Result: Fair Value of $21.65 (OVERVALUED)

However, this narrative still leans heavily on ELEVIDYS, where safety concerns and administrative delays, along with high research costs and litigation, could weaken the expected recovery story.

Another View: What The P/S Ratio Is Signalling

The analyst narrative frames Sarepta as around 6% overvalued at a fair value of $21.65, but the current P/S of 1.1x paints a different picture. The stock trades far below the US Biotechs industry average of 10.8x and the 7.2x peer average, and only slightly above its 1x fair ratio. For you, that mix of discount to sector and premium to the fair ratio raises a simple question: is the bigger risk overpaying, or underestimating what the market could move back toward if sentiment improves?

Next Steps

Unsure whether the tone of this story feels too cautious or not cautious enough? Act while the information is fresh and weigh both sides using the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Sarepta has sharpened your focus, do not stop here. Casting a wider net now could help you spot opportunities that others overlook.

• Target potential mispricing by scanning 44 high quality undervalued stocks that combine quality fundamentals with room for the market to reassess their prospects.
• Prioritise resilience by reviewing 74 resilient stocks with low risk scores that aim to keep volatility and financial stress in check.
• Hunt for future standouts by searching the screener containing 23 high quality undiscovered gems before they attract broad attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.